Related Experiment Video

Updated: Aug 18, 2026

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma

J I Cohen1

  • 1Laboratory of Clinical Infectious Diseases, Medical Virology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg. 10; Rm. 11N228, 10 Center Drive, MSC 1888, Bethesda, MD 20892, USA. jcohen@niaid.nih.gov

British Journal of Cancer
|April 28, 2005
PubMed

Insights

Certain statins show promise in treating Epstein-Barr virus (EBV)-lymphomas by inhibiting cell interactions and inducing apoptosis in transformed B cells. Simvastatin demonstrated a delay in lymphoma development in mouse models, suggesting potential therapeutic applications.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Statins are widely used for cholesterol reduction and cardiovascular event prevention.
  • Statins possess additional biological effects beyond lipid-lowering.
  • Epstein-Barr virus (EBV) is associated with certain B-cell lymphomas.

Purpose of the Study:

  • To investigate the potential of statins in treating EBV-associated lymphomas.
  • To explore the mechanisms by which statins affect EBV-transformed B cells.

Main Methods:

  • In vitro studies on EBV-transformed B cells.
  • Assessment of statin effects on cell-cell adhesion molecule interactions.
  • Evaluation of NF-kappaB activation and apoptosis induction.
  • In vivo studies using severe combined immunodeficiency (SCID) mice models.

Main Results:

  • Certain statins were found to inhibit interactions of adhesion molecules on EBV-transformed B cells.
  • These statins suppressed NF-kappaB activation and induced apoptosis in transformed B cells.
  • Simvastatin administration delayed the development of EBV-lymphomas in SCID mice.

Conclusions:

  • Statins exhibit anti-lymphoma activity against EBV-transformed B cells through multiple mechanisms.
  • Simvastatin shows potential as a therapeutic agent for EBV-lymphomas.
  • Further consideration of statins for treating selected EBV-lymphoma patients is warranted.

More Related Videos

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...